Cragg Endopro System I: Early Experience. I. Femoral Arteries

Clinical follow‐up in endovascular treatment for TASC C‐D lesions in femoro‐popliteal segment

“…In our series with stent grafts (Viabahn/Hemobahn 1 ) the primary patency at 12, 24, and 48 month of follow-up was 81.5%, 74.6%, and 74.6% respectively. Despite the good results with stent grafts [23][24][25], we believe that stents (covered or not) should not be used as first-line therapy, because they can exclude collaterals, and increase morbid-mortality in case of re-occlusion (where thrombolytic therapy will be necessary). Also, there is the additional risk of stent fracture which is highly related with reocclusion [26].…”

Covered Stents in the Treatment of Peripheral Arterial Aneurysms: Procedural Results and Midterm Follow-Up

“…This was not observed in previous studies [21][22][23], but has been reported when stent grafts are used for the treatment of atherosclerotic lesions [25]. In this initial experience we did not use antiplatelet or anticoagulant therapy, as our primary concern was to ensure the continued exclusion of the aneurysm from the circulation.…”

“…In this initial experience we did not use antiplatelet or anticoagulant therapy, as our primary concern was to ensure the continued exclusion of the aneurysm from the circulation. In view of this unacceptably high incidence of thrombosis, the use of oral anticoagulant therapy or antiplatelet therapy may be a useful therapeutic adjunct in such patients [25]. It may be relevant that all three patients who developed subclavian stent thrombosis had persisting neurologic sequelae that, by preventing mobilization of the upper limb, may have contributed to the development of stent thrombosis.…”

A Newly Designed Nitinol Stent: Early Clinical Experience in the Treatment of Iliac Artery Stenoses and Occlusions

“…Since the report published by Dotter et al in 1983 (6), several other reports have described clinical and experimental application of the nitinol stent (7, 8). The Strecker, Memotherm and Cragg stents are examples of nitinol stents which have recently become available (9-11). The advantages of such stents for intravascular applications are easy delivery, a high expansion rate, low metal to tissue ratio, and the lack of severe neointimal proliferation (12-14).…”